Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# ARTES Biotechnology

CDMO for microbial cell lines and processes

## Sitemaps

- [XML Sitemap](https://artes-biotechnology.biz/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Partnership with Provenance aims in new designer collagen peptides](https://artes-biotechnology.biz/partnership-with-provenance-aims-in-new-designer-collagen-peptides/) - Provenance precision fermentation platform, further developed and scaled up by ARTES, delivers pur, highly functional bioactive collagen without animal origin
- [Bringing microbial CDMO services to BIO International 2025 in Boston](https://artes-biotechnology.biz/bringing-microbial-cdmo-services-to-bio-international-2025-in-boston/) - ARTES, CDMO for microbial cell lines and process development, will exhibit at BIO International, Boston, USA and will be part of the German Pavilion (#3065)
- [ARTES presenting at BIO-Europe Stockholm](https://artes-biotechnology.biz/artes-presenting-at-bio-europe-stockholm/) - Langenfeld, Germany: – ARTES Biotechnology, the German-based biopharmaceutical CDMO specializing in development of microbial cell lines for recombinant proteins and vaccines, is returning to participate in Europe’s leading life sciences partnering conference, BIO-Europe 2024, this year in Stockholm for its 30th Anniversary. ARTES will have an exhibition booth at the conference (149) at the Stockholmsmässan
- [ARTES backs “Initiative against Corona”](https://artes-biotechnology.biz/artes-backs-initiative-against-corona-calls-for-vaccinations/) - Never again 2020: Let's get vaccinated - “Initiative against Corona” calls for vaccinations Health service provider NOVENTI and the four leading vaccine manufacturers in Germany want to increase the population's willingness to vaccinate through a Germany-wide campaign - “Dispute must give way to factual clarification” posters for all 19,000 pharmacies in Germany, among others
- [Head of Molecular Biology at ARTES](https://artes-biotechnology.biz/head-of-molecular-biology-at-artes/)
- [METAVAX®-Platform](https://artes-biotechnology.biz/metavax-platform/)
- [ARTES receives Renewal of French Research Tax Credit (CIR) Accreditation](https://artes-biotechnology.biz/1662-2/)
- [ARTES joins global combat against Corona](https://artes-biotechnology.biz/artes-joins-global-combat-against-corona/)
- [ARTES part of "Worldwide, researchers work on coronavirus vaccine"](https://artes-biotechnology.biz/artes-part-of-worldwide-researchers-work-on-coronavirus-vaccine/)
- [ARTES and Burnet Institute publish data on new malaria vaccine candidates](https://artes-biotechnology.biz/artes-and-burnet-institute-publish-data-on-new-malaria-vaccine-candidates/) - For more information: Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice.
- [VLP purification patent granted in EU](https://artes-biotechnology.biz/vlp-purification-patent-granted-in-eu/) - Artes is pleased to announce the issuance of a new patent for their VLP development and production platform. The patent is about a "Method for Separating of Virus like Particles from a Cell Suspension".
- [VLP Purification Patent granted in US](https://artes-biotechnology.biz/vlp-purification-patent-granted-in-us/) - ARTES is pleased to announce the enlargement of the protective aera for their VLP development and production platform patent . The patent is about a “Method for Separating of Virus like Particles from a Cell Suspension” and now valid in Europe and US.
- [Cellumed and ARTES Sign Development and License Agreement](https://artes-biotechnology.biz/cellumed-and-artes-sign-development-and-license-agreement/)
- [ARTES 20th Year Anniversary – a short overview](https://artes-biotechnology.biz/artes-20th-year-anniversary-a-short-overview/)
- [ARTES and Basic Pharma near completion of their joint rHSA project](https://artes-biotechnology.biz/artes-and-basic-pharma-near-completion-of-their-joint-rhsa-project/) - Geleen – Langenfeld, May 2024 ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer. ARTES, a leading company that specialized in developing and transferring recombinant cell lines
- [ARTES announce expansion of the management board](https://artes-biotechnology.biz/artes-announce-expansion-of-the-management-board/) - Langenfeld, Germany; 10th of January 2024 ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology and with Dr. Melanie Piontek, Business Development Director. Volker
- [ARTES' Proteins for Diagnostics](https://artes-biotechnology.biz/proteins-for-diagnostics/)
- [ARTES and Basic Pharma join in a strategic Collaboration](https://artes-biotechnology.biz/artes-and-basic-pharma-join-in-a-strategic-collaboration/) - ARTES Biotechnology and Basic Pharma join in a strategic Collaboration and Co-Marketing Partnership for Pharmaceutical Recombinant Protein Production Geleen – Langenfeld, October 2023 ARTES Biotechnology, a leading company specializing in development and transfer of recombinant cell lines and protein production processes from microbial expression systems and Basic Pharma, a pharmaceutical company focusing on niche
- [New Paper Published](https://artes-biotechnology.biz/new-paper-published/)
- [Features of ARTES´ Hansenula polymorpha protein production platform](https://artes-biotechnology.biz/features-of-artes-hansenula-polymorpha-protein-production-platform/)
- [ARTES attends BioEurope 2019](https://artes-biotechnology.biz/artes-attends-bioeurope-2019/)
- [ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates](https://artes-biotechnology.biz/artes-and-burnet-institute-publish-data-on-production-and-immunogenicity-of-malaria-transmission-blocking-vaccine-candidates/) - ARTES Biotechnology and Burnet Institute recently published data on the efficient production of malaria vaccine candidates using virus-like particles (VLP) presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies.
- [SplitCore – the latest milestone in ARTES´ vaccine development offer](https://artes-biotechnology.biz/splitcore-the-latest-milestone-in-artes-vaccine-development-offer/) - ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the University of Freiburg, Germany.
- [ARTES attends BioEurope Spring 2019](https://artes-biotechnology.biz/artes-attends-bioeurope-spring-2019/) - Meet us at the Bio-Europe Spring 2018 tak­ing place in Vienna, Austria March 25 -27. Volker Jenzelewski, Direc­tor Technology at ARTES, will be present in the One-on-One Part­ner­ing presenting ARTES' innovative range of cell line and process development solutions for bio-pharmaceutical and vaccine products.
- [ARTES and Minapharm joint forces](https://artes-biotechnology.biz/artes-and-minapharm-joint-forces/) - ARTES Biotechnology GmbH, Germany, and Minapharm Pharmaceuticals and Chemical Industries S.A.E., Egypt, jointly announced today the formation of a new strategic business pact, offering packet solution for biopharmaceutical processes . Aim of this new strategic business cooperation is to jointly out-license combinations of ARTES’ and Minapharm’s respective proprietary technologies and products to third parties
- [ARTES successfully completed EU funded project Plurivax](https://artes-biotechnology.biz/artes-successfully-completed-eu-funded-project-plurivax/) - ARTES Biotechnology explored very effective in a SME consortium vaccine developments for veterinary applications. Under the titel: “ERA-Net EuroTransBio-8: PLURIVAX, development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications, the EU cooperation was part of the 8th EuroTransBio call and was funded in the time period from
- [ARTES attends Bio-Europe Spring 2018](https://artes-biotechnology.biz/artes-attends-bio-europe-spring-2018/) - Meet us at the Bio-Europe Spring 2018 tak­ing place in Amsterdam March 12 -14. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing presenting ARTES' innovative range of cell line and process development solutions for bio-pharmaceutical and vaccine products. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a
- [ARTES brings new vaccine advances to veterinary ‘Dragons’ Den’](https://artes-biotechnology.biz/artes-brings-new-vaccine-advances-to-veterinary-dragons-den/) - ARTES will attend February’s European Animal Health Investment Forum in London and will present its innovative technologies to potential partners This will be ARTES’ second participation in the high prestige investment networking event, which is seen as the ‘Dragons’ Den’ of veterinary medicine. ARTES Managing Director, Dr. Michael Piontek, will use the forum to talk
- [ARTES attends Biofit 2017](https://artes-biotechnology.biz/artes-attends-biofit-2017/) - Meet us at the Biofit 2017 taking place in Strasbourg November 28 -29. Michael Piontek, Managing Director at ARTES, will be present in the One-on-One Partnering and we are present with our own booth (number F2). Contact us previously for organizing a personal meeting or drop us a notice via the partnering system. We look
- [ARTES receives French Research Tax Credit (CIR) Accreditation](https://artes-biotechnology.biz/artes-receives-french-research-tax-credit-cir-accreditation/) - ARTES Biotechnology GmbH today announced that it has just obtained governmental approval for 'Crédit d'Impôt Recherche' (CIR) for a three-year period from the French Ministry of Higher Education and Research (MESR). The French R&D tax credit CIR gives French companies the ability to claim tax relief on 30% on all generated costs outsourced to ARTES’
- [ARTES was part of a successful international consortium](https://artes-biotechnology.biz/artes-was-part-of-a-successful-international-consortium/) - EU Research Project Nano3Bio sums up: Promising achievements for winning future raw materials Since fossil raw materials are rapidly running out, their substitution by renewable resources is becoming increasingly important. In this process, the biological production of raw materials will have to play a leading role. The international project Nano3Bio, including ARTES Biotechnology has contributed
- [ARTES  received next grant of patent for METAVAX®](https://artes-biotechnology.biz/artes-received-next-grant-of-patent-for-metavax/) - ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-particle (VLP) technology platform METAVAX®. “The new patent integrates exactly in our existing patent portfolio and will further strengthen our technology offer”, said Dr. Melanie Piontek, Business Development Director of ARTES. “In combination with our proprietary yeast expression technology our
- [ARTES joins WAVESCATTER](https://artes-biotechnology.biz/artes-joins-wavescatter/) - A consortium of 5 companies and the Fraunhofer-Institut für Lasertechnik ILT, aim to develop under the name of WAVESCATTER („Winkelauflösende Wellenleiter-Streulichtsonde für die Inline-Prozessanalytik“) a new kind of scattered light sensor for precise inline particle analytic. The project will be funded for a three year period by the German Federal Ministry of Education and Research
- [BIO International Convention 2017](https://artes-biotechnology.biz/bio-international-convention-2017/) - Meet us at the BIO International Convention taking place in San Diego, CA, USA June 19 -22. Michael Piontek, Managing Director at ARTES, will be present in the One-on-One Partnering. Contact us previously for organizing a personal meeting or drop us a notice via the partnering system. We look forward to meeting you! www.convention.bio.org/2017
- [15 Years ARTES Biotechnology](https://artes-biotechnology.biz/15-years-artes-biotechnology/) - Toady, ARTES has 15 year anniversary. In 2002 at May 10th Michael Piontek founded ARTES as R&D company, specialized in developing yeast cell lines for recombinant protein production. In 15 years ARTES has positioned itself as valued partner for the pharmaceutical and life science industry and it is now specialized in developing whole biotechnology production processes.
- [ARTES attends European Animal Health Investment Forum](https://artes-biotechnology.biz/artes-attends-european-animal-health-investment-forum/) - ARTES will head for London’s elite Mayfair district in February to take part in the ‘Dragons Den’ of veterinary medicine, the European Animal Health Investment Forum. This will be ARTES’ first participation in the high prestige investment networking event. ARTES will be represented by its Managing Director, Dr. Michael Piontek, who will be talking in particular
- [ARTES, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development](https://artes-biotechnology.biz/artes-instraction-and-q-biologicals-join-forces-for-veterinary-vaccine-development/) - Under the title:” development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications”, in short “Plurivax”, the EU cooperation is part of the recent 8th EuroTransBio call and will be funded for a three year period supported by the German Federal Ministry of Education and Research (BMBF) and
- [ARTES and BioSun announce co-development for HPV vaccine](https://artes-biotechnology.biz/artes-and-biosun-announce-co-development-for-hpv-vaccine/) - Langenfeld, Germany / Tehran, Iran ARTES Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran. The agreed long-term collaboration involved the strength of both partners. ARTES Biotechnology GmbH (ARTES) is specialized in cell line and process development of virus like particle (VLP)
- [Sun Pharma & ICGEB sign exclusive deal on dengue vaccine - ARTES adds experience in VLP development and production](https://artes-biotechnology.biz/sun-pharma-icgeb-sign-exclusive-deal-on-dengue-vaccine-artes-adds-experience-in-vlp-development-and-production/) - NEW DELHI, India I October 19, 2016 International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine,
- [ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine](https://artes-biotechnology.biz/artes-and-burnet-institute-join-forces-to-develop-novel-hepatitis-c-vaccine/) - ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis C virus (HCV). An HCV vaccine is urgently needed to prevent re-infection in people treated through antiviral therapies and reverse the high global mortality rates from infection-related liver cirrhosis or liver cancer, estimated by
- [ARTES and Biosphere announce collaboration](https://artes-biotechnology.biz/artes-and-biosphere-announce-collaboration/) - ARTES Biotechnology, specialized in microbial cell line and process development for recombinant protein production and technology provider for high-quality biotechnological processes, join forces with the well-established contract manufacturing company Biosphere. Aim of this preferred cooperation is to offer a full range of services, starting from cell line generation up to industrial scale manufacturing in one
- [ARTES offers manufacturing of preclinical samples up to multi-gram scale](https://artes-biotechnology.biz/artes-offers-manufacturing-of-preclinical-samples-up-to-multi-gram-scale/) - ARTES Biotechnology, specialized in microbial cell line and process development for the pharmaceutical industry recently expanded its service portfolio and supplied samples for preclinical testing to a first client. “With the new equipped pilot plant for production of nonGMP material, we are now in the position to provide our clients with high quality preclinical test
- [ARTES and Boehringer Ingelheim Animal Health Announce Collaboration](https://artes-biotechnology.biz/artes-and-boehringer-ingelheim-animal-health-announce-collaboration/) - ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expression systems announces a collaboration with the global pharmaceutical company Boehringer Ingelheim Animal Health. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’
- [New Scientific Board Member](https://artes-biotechnology.biz/new-scientific-board-member-3/) - Prof. Dr. Holger Zorn, University of technology, Dortmund, leader of the work group technological biochemistry. Prof. Dr. Zorn is an expert in the field of industrial bioengineering and white biotechnology and here in detail for extraction of enzymes from basidiomycete fungi. We are really proud to welcome Prof. Zorn as our new board member and
- [New Scientific Board Member](https://artes-biotechnology.biz/new-scientific-board-member-2/) - Prof. Dr. em. Hermann Sahm As the former director of the Institute of Biotechnology at the Research Center of Jülich, Prof. Dr. em. Hermann Sahm`s main fields of interest in the last three decades were physiology, enzymology and molecular biology of biotechnical amino acid, vitamin and ethanol production by means of a variaty of different
- [ARTES enters into a partnership with Henkel in a 3-year research program](https://artes-biotechnology.biz/artes-enters-into-a-partnership-with-henkel-in-a-3-year-research-program/) - ARTES Biotechnology GmbH today announces the collaboration with Henkel in a joint three years research program that is granted by the German national BMBF (German Ministery of Education and Research) within the CLIB2021 cluster (Wettbewerb Industrielle Biotechnologie 2021). The cooperation aims at the development and manufacturing of peptides with adhesive properties. ARTES will apply its
- [Exclusive Cooperation between ARTES and the Ukrainian National Academy of Sciences](https://artes-biotechnology.biz/exclusive-cooperation-between-artes-and-the-ukrainian-national-academy-of-sciences/) - Langenfeld/Lviv, August 5th, 2009 ARTES announced today that it has signed an exclusive Marketing Agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. Matter of the agreement is that the NAS technology based on the yeast organism Hansenula polymorpha is now exclusively marketed and licensed by ARTES Biotechnology worldwide
- [ARTES is research partner of ChemBioTec project supported by Deutsche Stiftung Umwelt](https://artes-biotechnology.biz/artes-is-research-partner-of-chembiotec-project-supported-by-deutsche-stiftung-umwelt/) - ARTES Biotechnology today announces the collaboration with 5 other collaboration partners in a joint 28 months research program that is granted by the national Deutsche Stiftung Umwelt within the ChemBioTec initiative. The Deutsche Bundesstiftung Umwelt DBU is one of Europe's largest foundations and promotes innovative and exemplary environmental projects The funded project includes three academic
- [ARTES and Rhein Minapharm continue their successful product development collaboration](https://artes-biotechnology.biz/artes-and-rhein-minapharm-continue-their-successful-product-development-collaboration/) - Langenfeld and Cairo – ARTES Biotechnology and Rhein Minapharm Biogenetics jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology
- [Injectable Sustained Release Formulations of Therapeutic Proteins](https://artes-biotechnology.biz/injectable-sustained-release-formulations-of-therapeutic-proteins/) - Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a
- [ARTES steps further into the vaccine business by acquiring Anavax](https://artes-biotechnology.biz/artes-steps-further-into-the-vaccine-business-by-acquiring-anavax/) - ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique
- [BIO 2011, Washington DC](https://artes-biotechnology.biz/bio-2011-washington-dc/) - Meet us at the partnering "Business Forum" event of the Bio International Convention 2011 in Washington DC or contact us directly for a personal meeting! The Bio 2011 is taking place from June 27 - 30. Go to BIO website
- [New Scientific Board Member](https://artes-biotechnology.biz/new-scientific-board-member/) - Prof. PhD David Anderson Burnet Institute, Melbourne, Australia, Deputy Director, Burnet Senior Principal Fellow. Professor Anderson is an expert in Microbiology and Molecular Virology. He has focused his work on understanding the structure and assembly of hepatitis viruses, and the use of this information to design better diagnostics, vaccines and antiviral therapies for control of
- [ARTES and NL join in a strategic collaboration and co-marketing alliance](https://artes-biotechnology.biz/artes-and-nl-join-in-a-strategic-collaboration-and-co-marketing-alliance/) - ARTES, specialized in recom-binant protein production and process development from yeast expression systems and the US based company NL Biotech-nologies, owner and specialized in certain tech-nologies for production of vaccines and diagnostic proteins started a strategic collaboration. With signing this collaboration agreement the two companies combine their know-how and technologies in yeast expres-sion, process and
- [Strategic collaboration deal for vaccine development](https://artes-biotechnology.biz/strategic-collaboration-deal-for-vaccine-development/) - ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharma-ceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Aim of the long-term research cooperation is a new-product
- [Strategic cooperation between ARTES Biotechnology and PAC](https://artes-biotechnology.biz/strategic-cooperation-between-artes-biotechnology-and-pac/) - Artes and PAC join forces and combine their technologies and know-how. ARTES Biotechnology specializes in recombinant protein production, process development in microbial expression systems and is a technology provider for pharmaceutical processes, while PAC (Peschek Analytic Consulting) is highly skilled in the field of protein analysis and quality control. Together with PAC, ARTES will now
- [ARTES Biotechnology issued New Patent in Australia for VLP Technology](https://artes-biotechnology.biz/artes-biotechnology-issued-new-patent-in-australia-for-vlp-technology/) - ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique
- [ARTES Biotechnology and Midas Pharma signed Cooperation Contract](https://artes-biotechnology.biz/artes-biotechnology-and-midas-pharma-signed-cooperation-contract/) - ARTES announced the collaboration with Midas for strategic marketing opportunities. Aim of the cooperation is the finding of suitable partners for defined pharmaceuticals projects like vaccine and pharmaceutical target development or transfer of Biosimilar processes. ARTES is specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry whereas
- [ARTES Biotechnology and Bio Farma announce collaboration in vaccine development](https://artes-biotechnology.biz/artes-biotechnology-and-bio-farma-announce-collaboration-in-vaccine-development/) - ARTES and Bio Farma announced today to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved the strength of both partners. ARTES is specialized in cell line and process development, VLP based vaccines as well as in technology transfer for pharmaceutically relevant production processes whereas Bio Farma is involved in
- [ ARTES Biotechnology joins TA101 GOCLIN](https://artes-biotechnology.biz/artes-biotechnology-joins-ta101-goclin/) - A leading consortium of industrial partners has been awarded a grant by the Seventh Framework Program of the European Union for an innovative research and development project “TA101 GOCLIN: Clinical development of TA-101 for the treatment of rheumatoid arthritis“ (#606352). The aim of this Project is to take TA101, a small domain antibody developed by
- [EU Research Project "Nano3Bio" has Started – "Huge Potential" through Biotechnology](https://artes-biotechnology.biz/eu-research-project-nano3bio-has-started-huge-potential-through-biotechnology/) - ARTES Biotechnology GmbH is part of the international consortium While the oil is slowly but surely running out, renewable resources are becoming increasingly important. In future, the biological production of raw materials has to play an even greater role to meet the needs in an environmentally friendly manner. An international consortium of researchers and companies
- [Vaccine Emerging Markets](https://artes-biotechnology.biz/vaccine-emerging-markets/) - Meet us at the 2nd Annual Phacilitate Partnering for Vaccine Emerging Markets event in Amsterdam, May 28th -29th or contact us previously for a personal meeting! We look forward to meeting you! http://www.phacilitate.co.uk/vaccine-emerging-markets/
- [Strategic cooperation between ARTES & Sun Pharma](https://artes-biotechnology.biz/strategic-cooperation-between-artes-sun-pharma/) - ARTES Biotechnology has entered into a strategic collaboration with a subsidiary of Sun Pharmaceutical Industries Ltd, an international specialty pharmaceutical company with a diversified product portfolio headquartered in Mumbai/India. This step broadens ARTES' international client base and demonstrates its ability to attract blue chip pharmaceutical companies. Under the collaboration agreement, ARTES will be responsible to
- [Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project](https://artes-biotechnology.biz/malaria-transmission-blocking-vaccines-artes-and-burnet-announced-a-development-project/) - ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). The project will use exciting novel technology developed at the Burnet Institute. ARTES holds the international patent rights and adapted the platform to vaccine production (known as the

## Pages

- [ARTES Biotechnology](https://artes-biotechnology.biz/) - CDMO services for microbial cell line development, upstream and downstream processes, non-GMP manufacturing, and proprietary process transfer.
- [Downloads](https://artes-biotechnology.biz/downloads/) - Here in the download center you will find interesting information and facts about our company, our technology platforms, and our latest scientific papers.
- [Vertrag widerrufen](https://artes-biotechnology.biz/withdraw-from-contract/)
- [FAQ](https://artes-biotechnology.biz/faq/) - How to Find the Right Partner for Cell Line and Process Development in Yeast and E. coli? What is a microbial CDMO and what services do they provide?
- [Facility](https://artes-biotechnology.biz/facility/) - ARTES has S1 labs covering an area of ~ 900 m² in Langenfeld, Germany. We are specialized in developing microbial production processes for recombinant proteins.
- [Vaccines](https://artes-biotechnology.biz/vaccines/) - We transfer microbial cell lines & processes for production of VLP vaccines. The production processes result in highly immunogenic vaccines with low manufacturing costs.
- [Privacy Notice](https://artes-biotechnology.biz/datenschutzerklaerung/) - We would like to provide you with an overview. This overview is of how we process your personal data. It also covers your rights under data protection law.
- [ARTES](https://artes-biotechnology.biz/artes/) - CDMO and technology provider for recombinant protein production - ARTES is the expert in microbial cell line und process development
- [Process Development](https://artes-biotechnology.biz/process-development/) - up- and downstream process development of robust and reproducible microbial fermentation processes and increased strain productivity
- [VLP Vaccine Development](https://artes-biotechnology.biz/vlp-vaccine-development/) - Discover ARTES's innovative VLP vaccine platform, combining safety, efficacy, and cost-effectiveness for human and animal health solutions.
- [Microbial Cell Line Development](https://artes-biotechnology.biz/microbial-cell-line-development/) - Uncover the importance of well-developed microbial cell lines and detailed records in turning scientific ideas into market-ready products.
- [Technology Transfer](https://artes-biotechnology.biz/technology-transfer/) - Extensive list of recombinant protein products available as ‘ready-to-use’ microbial cell lines and processes; time and cost savings in project development
- [Biosimilar](https://artes-biotechnology.biz/biosimilar/) - biosimilar processes and the associated cell lines for licensing & technology transfer; processes based on yeast, E. coli or mammalian expression systems.
- [Enzymes](https://artes-biotechnology.biz/enzymes/) - microbial production processes for enzymes suitable for large-scale manufacturing at low cost-of-goods “ready-to-transfer”
- [Lab Reagents](https://artes-biotechnology.biz/lab-reagents/) - Lab Reagents - we've got a great range of recombinant protein antigens that'll help you out with your day-to-day lab work.
- [Manufacturing](https://artes-biotechnology.biz/manufacturing/) - Our technical experts ensure a smooth transition from the early stages of your recombinant protein project to commercial scale.
- [Proteins for Diagnostics](https://artes-biotechnology.biz/proteins-for-diagnostics/) - proteins for diagnostics ‣ shop your research reagents for your lab routine at our webshop ‣ all proteins are based on yeast or on E. coli.
- [Hansenula polymorpha](https://artes-biotechnology.biz/hansenula-polymorpha/) - ARTES uses one of the most important industrial expression systems, the methylotrophic yeast Hansenula polymorpha (syn. Pichia angusta).
- [Management Team](https://artes-biotechnology.biz/management-team/)
- [Career](https://artes-biotechnology.biz/career/)
- [News](https://artes-biotechnology.biz/news-2/)
- [Contact](https://artes-biotechnology.biz/contact/)
- [Imprint](https://artes-biotechnology.biz/imprint/)
- [Disclaimer](https://artes-biotechnology.biz/disclaimer/)
- [AGB](https://artes-biotechnology.biz/agb/)
- [Shipment](https://artes-biotechnology.biz/versandarten/)
- [Artes Biotechnology](https://artes-biotechnology.biz/artes-biotechnology-5/)
- [Zahlungsarten](https://artes-biotechnology.biz/bezahlmoeglichkeiten/) - Invoice You will receive an invoice from us after ordering. Please transfer the total amount to the account specified there within 14 days. Please note that the prices of products on our website do not include freight charges, duties, taxes or customs fees. Freight charges will be indicated in our order confirmation and will be
- [Datasheets](https://artes-biotechnology.biz/datasheets/)
- [Home](https://artes-biotechnology.biz/home/)
- [Shop](https://artes-biotechnology.biz/shop/)
- [Impressum](https://artes-biotechnology.biz/impressum/)
- [Widerrufsbelehrung](https://artes-biotechnology.biz/widerrufsbelehrung/)
- [Echtheit von Bewertungen](https://artes-biotechnology.biz/echtheit-von-bewertungen/)
- [Publications](https://artes-biotechnology.biz/publications/)
- [Video "About us"](https://artes-biotechnology.biz/video-about-us/)

## Products

- [T7 RNA Polymerase](https://artes-biotechnology.biz/product/t7-rna-polymerase/) - Order online! Give our recombinant T7 RNA polymerase, derived from yeast, a go and make your next experiment a hit! Product is top-notch with high enzyme activity
- [Enterokinase](https://artes-biotechnology.biz/product/enterokinase-2/) - Order online! Recombinant enterokinase (Bos Taurus) produced in Hansenula yeast. Cleaves after lysine at its cleavage site Asp-Asp-Asp-Asp-Lys. For research use
- [Monellin](https://artes-biotechnology.biz/product/enterokinase/)
- [HBsAg adw2](https://artes-biotechnology.biz/product/hbsag-adw2/) - Recombinant small surface antigen of human Hepatitis B virus, subtype adw2
- [Inorganic pyrophosphatase](https://artes-biotechnology.biz/product/inorganic-pyrophosphatase/) - Order online! Inorganic pyrophosphatase (iPPase, EC 3.6.1.1), a recombinant hydrolase cloned from S. cerevisiae and overexpressed in yeast H. polymorpha
- [Endoglycosidase H](https://artes-biotechnology.biz/product/endoglycosidase-h/) - Order online, recombinant Endoglucosidase H (Endo H) cloned from Streptomyces plicatus , tool for glycan analysis, high efficiency, high purity and bioactivity
- [HPV33 L1](https://artes-biotechnology.biz/product/rhpv52l1/) - Order online! Recombinant L1 Human Papilloma Virus (HPV) protein serotype 33, yeast derived, research tool, high quality, specific bioactivity
- [HPV18 L1](https://artes-biotechnology.biz/product/hpv18-l1/) - Order online! Recombinant L1 Human Papilloma Virus (HPV) protein serotype 18, yeast derived, research tool, high quality, specific bioactivity
- [HPV16 L1](https://artes-biotechnology.biz/product/hpv16-l1/) - Order online! Recombinant L1 Human Papilloma Virus (HPV) protein serotype 16, yeast derived, research tool, high quality, specific bioactivity
- [HPV11 L1](https://artes-biotechnology.biz/product/hpv11-l1/) - Order online! Recombinant L1 Human Papilloma Virus (HPV) protein serotype 11, yeast derived, research tool, high quality, specific bioactivity
- [HPV6 L1](https://artes-biotechnology.biz/product/rhpv6-l1/) - Order online! Recombinant L1 Human Papilloma Virus (HPV) protein serotype 6, yeast derived, research tool, high quality, specific bioactivity
- [HPV31 L1](https://artes-biotechnology.biz/product/hpv31-l1/) - Recombinant L1 protein of Human Papilloma Virus (HPV) serotype 31 produced in yeast Hansenula polymorpha. Top quality for your research. Order online!
- [INTERFERON ALPHA 2B](https://artes-biotechnology.biz/product/interferon-alpha2b/) - Buy online Interferon α2b, yeast derived, recombinant; application in research (RP-HPLC, analytical SEC, SDS-PAGE, activity assay, Western Blot). Order online!
- [INTERFERON ALPHA 2A](https://artes-biotechnology.biz/product/interferon-alpha/) - Buy online Interferon α2a, recombinant, yeast derived ; application in research (RP-HPLC, analytical SEC, SDS-PAGE, activity assay, Western Blot). Order online!
- [Brazzein](https://artes-biotechnology.biz/product/brazzein/) - Order online! Recombinant Brazzein, artificial protein sweetener. Isolated out of Pentadiplandra brazzeana. For R&D purposes in your laboratory (RP-HPLC, SEC, SDS-PAGE, etc.)
- [Human Serum Albumin](https://artes-biotechnology.biz/product/human-serum-albumin/) - Order yeast-derived recombinant Human Serum Albumin (rHSA) online. It's also animal component free. Get the best for your day-to-day R&D work in the lab!

## Categories

- [Allgemein](https://artes-biotechnology.biz/category/allgemein/)
- [Applications](https://artes-biotechnology.biz/category/applications/)
- [About us](https://artes-biotechnology.biz/category/about-us/)
- [Services](https://artes-biotechnology.biz/category/services/)
- [Platform Technology](https://artes-biotechnology.biz/category/platform-technology/)
- [Products](https://artes-biotechnology.biz/category/products/)
- [News](https://artes-biotechnology.biz/category/news/)

## Tags

- [2008](https://artes-biotechnology.biz/tag/2008/)
- [CDMO](https://artes-biotechnology.biz/tag/cdmo/)
- [Microbial cell line development](https://artes-biotechnology.biz/tag/microbial-cell-line-development/)
- [Bio International](https://artes-biotechnology.biz/tag/bio-international/)
- [precision fermentation](https://artes-biotechnology.biz/tag/precision-fermentation/)
- [collagen](https://artes-biotechnology.biz/tag/collagen/)

## Product categories

- [Antigens](https://artes-biotechnology.biz/product-categorie/artes-products/)
- [New](https://artes-biotechnology.biz/product-categorie/new/)
- [Enzymes](https://artes-biotechnology.biz/product-categorie/enzymes/)
- [Functional Proteins](https://artes-biotechnology.biz/product-categorie/proteins/)